📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
51 announcements match the current filters (relevance ≥ 5).
Hester Biosciences Q4 Consolidated PAT Surges 974% YoY; Recommends INR 11 Dividend
Hester Biosciences reported a massive 974% year-on-year surge in consolidated Q4 PAT to INR 165.46 million, driven by a 22% increase in revenue and significant margin expansion. For the full year FY26, consolidated PAT nearly doubled to INR 574.84 million despite a modest 7% revenue growth, reflecting improved operational efficiency and product mix. The Board has recommended a dividend of INR 11 per share (110%), while the Poultry Healthcare division remains the primary growth engine with 41% Q4 growth. However, the Animal Healthcare division continues to face headwinds from delayed government programs, declining 6% in Q4.
Key Highlights
Consolidated Q4 PAT jumped 974% YoY to INR 165.46 million; Standalone Q4 PAT rose 174% to INR 263.84 million.
Board recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.
Poultry Healthcare division revenue grew 41% in Q4 FY26, while Animal Healthcare revenue declined 6% due to government program delays.
Consolidated EBITDA margins improved significantly to 36% in Q4 FY26 from 17% in the previous year's quarter.
Successfully received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine during the quarter.
👀 What to Watch
The sharp recovery in profitability and strong dividend payout make this a positive result for shareholders. Investors should monitor the scale-up of the new BSL 3 facility and the recovery of the Animal Healthcare segment as government tenders resume.
Hester Biosciences Recommends ₹11 Dividend; FY26 PAT Surges 64% to ₹521 Million
Hester Biosciences has recommended a final dividend of ₹11 per share for FY26, representing a 110% payout on face value. The company reported a strong financial performance with annual standalone Profit After Tax (PAT) rising 64% to ₹521 million, driven by significant growth in the Poultry Healthcare segment. Quarterly performance was particularly robust, with Q4 PAT jumping to ₹263.84 million from ₹96.35 million in the previous year. Additionally, the board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a three-year term.
Key Highlights
Recommended a final dividend of ₹11 per equity share (110%) for the financial year 2025-26.
Standalone annual Profit After Tax (PAT) increased by 63.6% YoY to ₹521 million.
Q4 FY26 Revenue from operations grew 22% YoY to ₹937.13 million compared to ₹766.72 million.
Poultry Healthcare segment revenue grew to ₹2,061.31 million in FY26 from ₹1,665.83 million in FY25.
Earnings Per Share (EPS) improved significantly to ₹61.24 for FY26 compared to ₹37.43 in FY25.
👀 What to Watch
Investors should consider the strong bottom-line growth and healthy dividend payout as a sign of improved operational efficiency. The significant jump in Q4 margins and Poultry segment growth makes this a positive development for long-term holders.
Hester Biosciences Q4 Net Profit Jumps 174% to ₹26.38 Cr; Declares ₹11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to ₹937.13 million. Net profit for the quarter surged 174% to ₹263.84 million, significantly bolstered by an exceptional gain of ₹69.96 million from the sale of a subsidiary. For the full year FY26, the company achieved a net profit of ₹521.00 million, a 64% increase over FY25. The Board has recommended a healthy dividend of ₹11 per share (110% of face value).
Key Highlights
Q4 FY26 Standalone Revenue rose 22.2% YoY to ₹937.13 million compared to ₹766.72 million.
Standalone Net Profit for Q4 surged to ₹263.84 million from ₹96.35 million in the previous year.
Recommended a final dividend of ₹11 per equity share for the financial year 2025-26.
Poultry Healthcare segment revenue grew 24% in FY26, reaching ₹2,061.31 million.
Full-year FY26 Earnings Per Share (EPS) increased to ₹61.24 from ₹37.43 in FY25.
👀 What to Watch
Investors should view the strong recovery in the poultry segment and the significant jump in annual profitability as positive indicators. The stock remains attractive for long-term investors given the consistent dividend payout and the operationalization of new BSL-3 facilities.
Ester Industries Q4 PAT Surges 301% to ₹7.9 Cr; Proposes ₹0.25 Dividend
Ester Industries reported a strong recovery in Q4 FY26 with consolidated revenue growing 7.2% YoY to ₹345.1 crore and PAT surging 301% to ₹7.9 crore. While the full year FY26 ended in a consolidated loss of ₹27.5 crore, the company saw significant margin expansion in the final quarter due to anti-dumping duties on BOPET films and favorable regulatory shifts. The Specialty Polymers and rPET segments showed robust growth, with rPET revenue increasing 3.6x YoY. Additionally, the company successfully raised ₹165.25 crore through share warrants, strengthening its capital position.
Key Highlights
Consolidated Q4 PAT jumped 301% YoY to ₹7.9 crore, with EBITDA margins improving to 12.6%.
Full-year FY26 consolidated revenue grew 7.2% to ₹1,392.7 crore, despite a net loss of ₹27.5 crore for the year.
rPET segment revenue grew by 3.6x YoY to ₹59.3 crore, supported by Plastic Waste Management Rules.
Successfully secured ₹165.25 crore against a ₹175 crore share warrant issue from promoters and investors.
Board of Directors proposed a dividend of ₹0.25 per share for the financial year ended March 31, 2026.
👀 What to Watch
Investors should focus on the sharp Q4 turnaround and the growth in high-margin specialty segments as indicators of a recovery trend. The successful capital infusion and anti-dumping protections provide a better outlook for FY27.
Ester Industries Q4 PAT Surges 301% to ₹7.9 Cr; Proposes ₹0.25 Dividend
Ester Industries reported a significant turnaround in Q4 FY26, with consolidated revenue growing 7.2% YoY to ₹345.1 crore and PAT surging 301% to ₹7.9 crore. Although the company faced a consolidated loss of ₹27.5 crore for the full year FY26, the quarterly performance indicates a recovery in the BOPET film segment due to anti-dumping duties and improved global pricing. The company also demonstrated strong growth in its sustainable rPET segment, which saw revenues grow 3.6x to ₹59.3 crore. Additionally, a successful fundraise of ₹165.25 crore via share warrants has strengthened the balance sheet.
Key Highlights
Q4 Consolidated PAT jumped 301% YoY to ₹7.9 crore, while EBITDA rose 10.7% to ₹43.3 crore.
rPET revenue increased by 258% to ₹59.3 crore in FY26, supported by Plastic Waste Management Rules.
Specialty Polymers revenue grew 16% to ₹179.3 crore in FY26, with sales volumes up 21%.
Successfully secured ₹165.25 crore against a ₹175 crore share warrant issue for capital infusion.
Board proposed a dividend of ₹0.25 per share for FY26 despite a full-year consolidated loss.
👀 What to Watch
Investors should focus on the improving margins in the BOPET segment and the rapid scaling of the high-growth rPET business. The successful capital infusion and return to quarterly profitability suggest a positive outlook for FY27.
Ester Industries Q4 PAT Surges to ₹7.9 Cr; Proposes ₹0.25 Dividend and Secures ₹165 Cr Funding
Ester Industries reported a strong turnaround in Q4 FY26 with consolidated PAT rising to ₹7.9 crores from ₹1.96 crores YoY, driven by recovering margins in the BOPET film segment. While the full year FY26 resulted in a consolidated loss of ₹27.5 crores due to earlier headwinds, Q4 revenue grew 7.2% YoY to ₹345.1 crores. The company successfully raised ₹165.25 crores through share warrants, signaling strong promoter confidence. Management highlighted significant growth in sustainable segments, with rPET revenue increasing 3.6x YoY to ₹59.3 crores.
Key Highlights
Q4 FY26 consolidated EBITDA increased 10.7% YoY to ₹43.3 crores with margins at 12.6%.
Specialty Polymer segment volumes grew 21% in FY26, reaching 3,836 MT.
rPET sales volume surged by 258% in FY26 to 5,325 MT, driven by Plastic Waste Management Rules.
Board recommended a dividend of ₹0.25 per equity share (5% of face value).
Core operational EBITDA margin for Q4 stood at 15.5% excluding non-cash MTM losses of ₹10.2 crores.
👀 What to Watch
Investors should note the significant Q4 recovery and the shift towards high-margin specialty and recycled products which are reducing cyclicality. The successful capital infusion and anti-dumping duties on Chinese imports provide a positive outlook for margin expansion in FY27.
Ester Industries Recommends ₹0.25 Dividend and Appoints New Internal Auditors
Ester Industries has announced its audited financial results for the fiscal year ended March 31, 2026, reporting a consolidated net loss for the period. Despite the loss, the Board of Directors has recommended a final dividend of ₹0.25 per equity share of face value ₹5. The company also strengthened its governance by appointing Nangia Global Advisors LLP as Internal Auditors and re-appointing R J Goel & Co. as Cost Auditors for FY 2026-27. The statutory auditors, Walker Chandiok & Co LLP, issued an unmodified opinion on the standalone financial results.
Key Highlights
Recommended a final dividend of ₹0.25 per equity share (5% of face value) for FY 2025-26.
Appointed M/s. Nangia Global Advisors LLP as Internal Auditors for the financial year 2026-27.
Re-appointed M/s. R J Goel & Co. as Cost Auditors for the upcoming fiscal year.
Reported a consolidated net loss for the year ended March 31, 2026, as per the auditor's report.
Statutory auditors provided an unmodified opinion on the standalone financial results for the year.
👀 What to Watch
Investors should analyze the full financial statements to identify the drivers behind the consolidated net loss and evaluate if the dividend payout is sustainable. Monitor the company's operational performance in the coming quarters to see if the new internal audit controls improve cost management.
Ester Industries Recommends Final Dividend of Rs 0.25 per Share for FY26
The Board of Ester Industries has recommended a final dividend of Rs 0.25 per equity share for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming Annual General Meeting. While the company is maintaining a payout, the statutory auditor's report highlights that the group incurred a consolidated net loss for the fiscal year. Additionally, the company has appointed Nangia Global Advisors LLP as new internal auditors for FY 2026-27.
Key Highlights
Recommended a final dividend of Rs 0.25 per equity share of face value Rs 5 each.
Auditor's report indicates a consolidated net loss for the financial year ended March 31, 2026.
Nangia Global Advisors LLP appointed as Internal Auditors for the 2026-27 financial year.
M/s. R J Goel & Co. re-appointed as Cost Auditors for the 2026-27 financial year.
👀 What to Watch
Investors should weigh the dividend against the reported consolidated net loss for the year. It is advisable to review the detailed financial results to understand the drivers behind the loss before making further investment decisions.
Ester Industries Approves FY26 Results, Recommends Rs 0.25 Final Dividend
Ester Industries Limited has approved its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs. 0.25 per equity share, representing a 5% payout on the face value of Rs. 5. Notably, the auditor's report indicates that while the company was profitable on a standalone basis, it recorded a consolidated net loss for the full financial year. The company also refreshed its audit team by appointing Nangia Global Advisors LLP as Internal Auditors.
Key Highlights
Recommended a final dividend of Rs. 0.25 per equity share for the financial year 2025-26.
Reported a consolidated net loss for the financial year ended March 31, 2026.
Reported a standalone net profit for the financial year ended March 31, 2026.
Appointed M/s. Nangia Global Advisors LLP as Internal Auditors for the financial year 2026-27.
👀 What to Watch
Investors should scrutinize the full financial statements to understand the specific factors causing the consolidated loss despite standalone profitability. The minimal dividend and consolidated loss suggest a need for caution regarding the company's subsidiary performance.
Ester Industries Allots 67.08 Lakh Equity Shares on Warrant Conversion at Rs 158/Share
Ester Industries has approved the allotment of 67,08,851 equity shares following the conversion of warrants originally issued in November 2024. The shares were issued at a price of Rs 158 each, which includes a premium of Rs 153 per share. Notably, the promoter, Mr. Arvind Singhania, subscribed to 37,97,468 shares, while the remaining 29,11,383 shares were allotted to public category entities. This conversion has increased the company's total paid-up equity share capital to approximately Rs 52.15 crore.
Key Highlights
Allotment of 67,08,851 equity shares of face value Rs 5 each upon warrant conversion
Conversion price set at Rs 158 per share, including a premium of Rs 153
Promoter Arvind Singhania acquired 37,97,468 shares, representing over 56% of the allotment
Total paid-up capital increased to Rs 52,14,75,210 comprising 10,42,95,042 shares
Six public category entities, including K&K Ventures and various foundations, received 29,11,383 shares
👀 What to Watch
Investors should view the promoter's significant participation in the warrant conversion as a positive sign of confidence in the company's future. While there is a minor equity dilution, the capital infusion at Rs 158 per share provides a supportive valuation benchmark.
Ester Industries Proposes Leadership Re-designation and Remuneration Hike to ₹3 Crore
Ester Industries has issued a postal ballot notice seeking shareholder approval for significant leadership changes and compensation revisions. Mr. Arvind Singhania is set to transition from Managing Director and CEO to a Non-Executive Chairman role effective March 26, 2026. Additionally, the company is proposing a salary hike for Whole-time Director Mr. Ayush Vardhan Singhania, with a new annual remuneration range of ₹2.70 Crores to ₹3.00 Crores. Shareholders can cast their votes via e-voting between April 24 and May 23, 2026.
Key Highlights
Mr. Arvind Singhania to transition from MD & CEO to Non-Executive Chairman effective March 26, 2026
Proposed remuneration for Whole-time Director Mr. Ayush Vardhan Singhania increased to ₹2.70 Cr - ₹3.00 Cr per annum
Remote e-voting period scheduled from April 24, 2026, to May 23, 2026
Postal ballot results to be declared on or before May 26, 2026
👀 What to Watch
Investors should monitor the leadership transition as the current CEO moves to a non-executive role, potentially signaling a succession plan. Evaluate whether the proposed remuneration increase for the Whole-time Director is justified by the company's recent financial performance.
Ester Industries Appoints Vaibhav Jha as CEO; Arvind Singhania Transitions to Chairman
Ester Industries has announced a major leadership transition with Mr. Vaibhav Jha appointed as the new Chief Executive Officer effective March 27, 2026. Mr. Jha, an MBA from IIT Bombay, brings over 21 years of experience from top-tier organizations including Reliance Industries and Infosys. Concurrently, co-founder Mr. Arvind Singhania will step down from his executive role as MD and CEO to become the Non-Executive Chairman after 40 years of service. This move represents a significant shift towards professional management while maintaining founder oversight at the board level.
Key Highlights
Mr. Vaibhav Jha appointed as CEO effective March 27, 2026, with 21+ years of multi-industry experience.
Co-founder Mr. Arvind Singhania transitions to Non-Executive Chairman after leading the company since 1985.
New CEO Vaibhav Jha holds an MBA from IIT Bombay and previously worked at Reliance Industries and Infosys.
The leadership change is subject to approval from the company's members via a postal ballot.
Mr. Ayush Vardhan Singhania continues as Whole Time Director, maintaining family representation in management.
👀 What to Watch
Investors should monitor the company's operational performance and strategic shifts under the new professional CEO over the next few quarters. The transition from a founder-led to a professionally-managed structure is generally positive for long-term governance but requires a 'watch' approach during the initial phase.
Ester Industries Appoints Vaibhav Jha as CEO; Arvind Singhania Transitions to Chairman
Ester Industries has announced a major leadership transition effective March 27, 2026. Co-founder Mr. Arvind Singhania is moving from his role as Managing Director and CEO to become a Non-Executive Chairman, providing continued strategic guidance. Mr. Vaibhav Jha, a professional with over 21 years of experience at Reliance Industries and Infosys, has been appointed as the new CEO. This move signals a shift towards professional management while maintaining founder oversight through the Board.
Key Highlights
Mr. Vaibhav Jha appointed as Chief Executive Officer effective March 27, 2026
Mr. Arvind Singhania re-designated as Non-Executive Non-Independent Director and Chairman
New CEO Vaibhav Jha brings 21+ years of experience from reputed firms like Reliance and Infosys
Mr. Singhania, a co-founder with 40 years of experience, will continue to lead the Board
The management change is subject to approval from shareholders via a Postal Ballot
👀 What to Watch
Investors should monitor the company's performance under the new professional leadership to see if Mr. Jha can drive higher growth. The transition appears stable as the founder remains on the board to ensure continuity.
Ester Industries Appoints Vaibhav Jha as CEO; Arvind Singhania Moves to Non-Executive Chairman
Ester Industries has announced a major leadership transition with the appointment of Mr. Vaibhav Jha as the new Chief Executive Officer effective March 27, 2026. Mr. Jha, an MBA from IIT Bombay, brings over 21 years of experience from top-tier organizations like Reliance Industries and Infosys. Concurrently, co-founder Mr. Arvind Singhania, who has over 40 years of experience, will transition from his role as Chairman & CEO to Non-Executive Chairman. This move appears to be a strategic step towards professionalizing the management while retaining the founder's oversight.
Key Highlights
Mr. Vaibhav Jha appointed as CEO effective March 27, 2026, following 21+ years of global experience.
Co-founder Mr. Arvind Singhania transitions to Non-Executive Chairman after 40 years of leadership.
Mr. Jha's professional background includes roles at Reliance Industries, Infosys, and GEP Worldwide.
The board has approved a Postal Ballot to seek shareholder approval for the re-designation of the Chairman.
Updated list of Key Managerial Personnel (KMP) established for materiality disclosures under SEBI regulations.
👀 What to Watch
Investors should monitor the company's performance under the new CEO to see if there are any shifts in strategic direction. The transition is likely to be smooth as the founder remains on the board as Chairman to provide continuity.
Ester Industries Shareholders Approve MD Re-appointment and Key Related Party Transactions
Ester Industries Limited has announced the successful passage of five resolutions via postal ballot, ensuring leadership continuity and regulatory compliance for related party transactions. Shareholders approved the re-appointment of Mr. Arvind Singhania as Managing Director with 99.44% of the votes and Mr. Pradeep Kumar Rustagi as Whole-time Director with 99.98% support. Furthermore, material related party transactions with Ester Loop Infinite Technologies, Wilemina Finance Corporation, and Mr. Arvind Singhania were all approved with majorities exceeding 99.4%. These results reflect strong shareholder confidence in the company's current leadership and governance.
Key Highlights
Special Resolution for re-appointment of Mr. Arvind Singhania as MD passed with 99.44% favor.
Special Resolution for re-appointment of Mr. Pradeep Kumar Rustagi as WTD passed with 99.98% favor.
Three Ordinary Resolutions for material Related Party Transactions approved with over 99.4% majority each.
Total of 8,206,120 votes were polled for the MD re-appointment resolution (excluding interested promoters).
The voting period concluded on March 21, 2026, with results declared on March 24, 2026.
👀 What to Watch
The high approval ratings for management re-appointments suggest stable leadership, which is a positive sign for long-term holders. Investors should continue to monitor the nature of the approved related party transactions in future financial disclosures.
Hester Biosciences Credit Rating Downgraded to CARE BBB; Stable by CARE Ratings
CARE Ratings has downgraded Hester Biosciences' long-term bank facilities from 'CARE BBB+; Stable' to 'CARE BBB; Stable' and short-term ratings from 'A2' to 'A3+'. The downgrade follows a review of the company's FY25 audited and 9MFY26 unaudited financial performance. Management has labeled this downgrade as 'transitional,' pointing towards recent improvements in operating margins, ROCE, and debt coverage ratios post-September 2025. The company maintains adequate liquidity for its debt obligations and has recently secured a manufacturing license for the Avian Influenza H9N2 vaccine.
Key Highlights
Long-term bank facilities downgraded to CARE BBB; Stable from CARE BBB+; Stable
Short-term bank facilities downgraded to CARE A3+ from CARE A2
Total bank facilities rated by CARE Ratings amount to ₹131.47 crore
Management reports improved debt coverage indicators in H1FY26 despite the rating action
Company holds 75% global market share in PPR vaccine and 35% Indian market share in poultry vaccines
👀 What to Watch
Investors should exercise caution due to the credit downgrade, which may increase future borrowing costs. Monitor upcoming quarterly results to see if the management's claim of a 'transitional' phase reflects in actual bottom-line improvement and debt reduction.
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has approved the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will no longer be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. The transaction is expected to be completed within three months and represents a strategic rationalization of the company's subsidiary portfolio.
Key Highlights
Divesting 43.81% stake in Texas Lifesciences for an aggregate value of INR 92 million
Hester will retain an 11% equity stake and continue business relations with TLPL
TLPL FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million
Over 97% of TLPL's sales were internal to Hester, resulting in elimination during consolidation
The share transfer transaction is expected to be completed within a 3-month period
👀 What to Watch
Investors should note this as a portfolio streamlining move that unlocks INR 92 million in cash without significantly impacting consolidated revenue due to the high volume of internal sales. Monitor for any impact on procurement margins as TLPL moves from a subsidiary to an external supplier.
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has announced the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will cease to be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. This move allows Hester to unlock capital while maintaining a strategic business relationship with the entity.
Key Highlights
Divesting 43.81% stake out of 54.81% total holding in Texas Lifesciences Private Limited.
Total aggregate consideration for the sale is INR 92 million.
TLPL's FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million.
Hester will maintain an 11% equity stake and continue business operations with TLPL.
The transaction is expected to be completed within three months from March 5, 2026.
👀 What to Watch
Investors should watch for the impact on consolidated margins since TLPL's internal sales were previously eliminated, and monitor the utilization of the INR 92 million proceeds.
Hester Biosciences Re-appoints Rajiv Gandhi as CEO & MD for 3 Years with 99.54% Approval
Hester Biosciences has announced the successful re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director for a three-year term effective from April 1, 2026. The special resolution was passed via a postal ballot process with an overwhelming 99.54% of valid votes cast in favor. While the promoter group showed 100% support, a significant majority of the small institutional voting block (99.24%) voted against the resolution. This move ensures leadership continuity for the company through March 2029.
Key Highlights
Special resolution for re-appointment of Rajiv Gandhi as CEO & MD passed with 99.54% majority.
The new term is effective for three years from April 1, 2026, to March 31, 2029.
Total valid votes cast represented 4,075,085 shares, with 4,056,419 votes in favor.
Promoter group cast 3,451,082 votes, showing 100% internal support for the leadership.
Public institutional holders showed 99.24% dissent, though this represented only 18,570 shares.
👀 What to Watch
Investors should take confidence in the leadership continuity which supports long-term strategic stability. No immediate action is required as the current management remains at the helm.
Ester Industries Seeks Approval for ₹1,463 Cr RPT and Leadership Re-appointments
Ester Industries has issued a postal ballot notice to re-appoint its Chairman & CEO, Arvind Singhania, and Executive Director, Pradeep Kumar Rustagi, for three-year terms starting April 2026. A major highlight is the request for shareholder approval for material related party transactions (RPT) worth up to ₹1,463 crore with its associate company, Ester Loop Infinite Technologies, for FY 2026-27. Additionally, the company seeks a ₹380 crore limit for corporate guarantees from its promoter entity, Wilemina Finance Corporation. These resolutions aim to ensure leadership continuity and facilitate large-scale operational funding and trade.
Key Highlights
Re-appointment of Arvind Singhania as MD (Chairman & CEO) for 3 years effective April 1, 2026
Proposed material Related Party Transactions with associate ELITe totaling up to ₹1,463 crore for FY27
Approval sought for corporate guarantees up to ₹380 crore from holding company Wilemina Finance Corporation
Re-appointment of Pradeep Kumar Rustagi as Whole-Time Director for a further 3-year term
Postal ballot results to be declared on or before March 23, 2026
👀 What to Watch
Investors should review the explanatory statement for the ₹1,463 crore RPT to ensure terms are at arm's length and beneficial for the company's margins. Leadership stability is positive, but the scale of transactions with the associate company warrants close monitoring.
